(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Cyclone causes blackout, flight chaos in Brazil's Sao Paulo - 2Outside Lovers' Decision: Favored Climbing Rucksacks
- 3Treasure trove found in Egyptian tomb solves ancient mystery
- 4Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 56 Natural products High In Vitamins,Which One Do You Like to Eat
- Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- 'I was diagnosed with incurable brain cancer on holiday'
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- The Iran war’s energy security legacy
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- Churches and politicians in South Sudan call for 'lasting peace' in Easter messages
- Opening Your True capacity: 12 Techniques for Personal growth
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- 41 Young Men Die in South Africa After Circumcision Initiation
